Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. - Wikidata - awgldk - TriplyDB

Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial.

Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial.

http://www.wikidata.org/entity/Q36483341

about

Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research Immunotherapy: New Strategies for the Treatment of Gynecologic Malignancies Therapy of human papillomavirus-related disease HPV vaccine: Current status and future directions Perspectives for therapeutic HPV vaccine development Cross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines Influence of dendritic cells on viral pathogenicity Potential anti-HPV and related cancer agents from marine resources: an overview.hrHPV E5 oncoprotein: immune evasion and related immunotherapies.Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11-001.Immunotherapy for cervical cancer: Research status and clinical potential Immune therapy for human papillomaviruses-related cancers.Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses.Neem leaf glycoprotein partially rectifies suppressed dendritic cell functions and associated T cell efficacy in patients with stage IIIB cervical cancer.Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets.Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients.Therapeutic Vaccine Strategies against Human Papillomavirus.Induction of robust cellular immunity against HPV6 and HPV11 in mice by DNA vaccine encoding for E6/E7 antigen.Targeted treatments for cervical cancer: a review.Trial watch: Dendritic cell-based interventions for cancer therapy A novel dendritic cell targeting HPV16 E7 synthetic vaccine in combination with PD-L1 blockade elicits therapeutic antitumor immunity in mice.New Approaches to Immunotherapy for HPV Associated Cancers.Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine Dendritic cells: a critical player in cancer therapy?Peptide-based vaccines for cancer: realizing their potential.A novel CD4 T-cell epitope described from one of the cervical cancer patients vaccinated with HPV 16 or 18 E7-pulsed dendritic cells.Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies Cervical Cancer: Development of Targeted Therapies Beyond Molecular Pathogenesis.Immunologic treatments for precancerous lesions and uterine cervical cancer.Next-generation treatment strategies for human papillomavirus-related head and neck squamous cell carcinoma: where do we go?Recent progress in vaccination against human papillomavirus-mediated cervical cancer.Immunotherapy and targeted therapy for cervical cancer: an update.Cervical cancer screening in the era of HPV vaccination: A review of shifting paradigms in cytopathology.Current state in the development of candidate therapeutic HPV vaccines Effects of Portulaca oleracea L. Polysaccharides on Phenotypic and Functional Maturation of Murine Bone Marrow Derived Dendritic Cells.Immunotherapeutic targeting of established sarcoma in Swiss mice by tumor-derived antigen-pulsed NLGP matured dendritic cells is CD8+ T-cell dependent.Novel Approaches for Vaccination Against HPV-Induced Cancers.The current state of therapeutic and T cell-based vaccines against human papillomaviruses.Targeting Persistent Human Papillomavirus Infection.

P2860

Q21245661-C972A670-D860-4642-9CEB-9B182E61FF00 Q26744094-3DCDD1EA-8AF5-4B1C-8FDC-8A346F201428 Q26770607-A448FCBE-F519-4AA1-B693-7F3E82A27F8A Q27007473-C4D7301A-8F7C-4BFF-949C-A9072EF61F93 Q27026524-98A76861-5288-49F5-8F07-DF8E80B6871C Q28069272-9F2FD0DF-2EDB-4606-A09A-735EA1A33D3A Q28085724-88A98F44-FFC5-47B7-BE08-09DEFAB5BA2B Q33489629-C661279C-9FB6-476E-BB98-45798E1E738D Q33575647-7D968A13-0606-44A8-9555-476691E3F663 Q33730462-5DEB69F3-E086-4033-B4E8-5EA54CF453F8 Q33908553-36B47A10-E7BB-4C54-9057-9C6440868F40 Q34033763-77BD95E8-0B92-4CF4-8AD1-0E048C941EA7 Q34657561-8A2CC3F4-4B2B-4F65-AE23-38F5011F7251 Q35049821-1E1DF41D-3438-476D-AE70-1B701AD957AD Q35066357-B3612C0C-F527-4DCF-B070-54D6FB0A6BD3 Q35550108-996FA584-CAC5-481B-884C-E5EBC68139B2 Q35748591-2977B1EA-64C8-4AA4-8FC2-3682AC359DD1 Q35826752-2CDCA437-8A13-4C58-A6DE-87A95A7D5447 Q36184362-0D207095-A790-4B40-84C6-1769AD6BDFC1 Q36384032-50453FF6-3D1F-4F8D-AAB8-5BC3EFA53F4D Q36388529-18576F3E-C63C-4DAE-B713-507CCD55130E Q37079131-A0B3A12A-2241-4252-AB3A-7D369D645C43 Q37137430-A0FFEF65-DEFD-4F7B-8635-920930B0F1D6 Q37224420-F88C8984-0CC7-4EBA-BA38-84335D6AAAAF Q37276138-596E0A1D-C657-440C-B791-35E28FA72C50 Q37340462-692C6365-5166-4A78-A50F-66669B7626D7 Q37434590-F61861A8-1872-4B5A-B4A5-9DB4F17514CB Q37494787-A3C5489D-554A-43CD-A350-185F994F1F03 Q37579334-409C335B-059A-4DA8-BF58-A237D2CF00AA Q37703113-6280419F-A181-4139-88AE-98C68C5D4831 Q37943790-648E27A3-7186-47D0-9D28-5AD0BF02D23B Q38370782-98184634-9E58-4AD9-8BAE-A1693E73BE1E Q38633525-8648D969-213C-45D6-97AE-B4574F4FBB00 Q38673879-F7E7A145-36C0-44B9-A3B7-7787D778DBA9 Q38743922-153D31E4-FFB4-4C8A-95C7-4441A9E15C7C Q38848551-50448454-733C-4A57-B751-597813258B0B Q38950014-BC863BC6-AA60-4E37-8BE2-75C258D2ACF0 Q39033362-BF5BAB3A-A374-4772-8AA9-615F13E37E18 Q39033576-3EEB9B0A-0972-49DB-901E-419EA6B7C2BB Q40078375-1C6DEBCB-BAE9-4A51-B61C-A2D85DA0EC38

P2860

Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial.

http://www.wikidata.org/entity/Q36483341

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Human papillomavirus type 16 a ...... phase I escalating-dose trial.

@ast

Human papillomavirus type 16 a ...... phase I escalating-dose trial.

@en

type

label

Human papillomavirus type 16 a ...... phase I escalating-dose trial.

@ast

Human papillomavirus type 16 a ...... phase I escalating-dose trial.

@en

prefLabel

Human papillomavirus type 16 a ...... phase I escalating-dose trial.

@ast

Human papillomavirus type 16 a ...... phase I escalating-dose trial.

@en

P1433

Q36483341-1D0C7E64-7FD3-475D-A4EB-B2C5DB78407D

P1476

Q36483341-9AA52F54-197F-4B46-A83A-2C0D24BF9092

P2093

Q36483341-05D6880F-FFDE-4CA3-941E-BB1C666DA1D5

Q36483341-268C6361-00EC-4140-A7DA-82EEB20F8CD1

Q36483341-38FE7231-B403-44BE-8509-919974C18DC7

Q36483341-4D09BF58-FE02-4792-B7B7-7D51545AA970

Q36483341-633E8A10-4D92-474E-836F-4C23B68240C2

Q36483341-6FFFB67B-7752-4C9D-8303-EA1FBCC20F11

Q36483341-A0194CF2-34D4-47D2-8185-D545DBA5E7C4

Q36483341-C34E89C4-B02D-4ABD-A50D-B34A3B704C14

P2860

Q36483341-0D368EE1-58BA-4E74-A71A-32E294893AB9

Q36483341-1012814F-DCAB-45CE-A4F4-702470309AAF

Q36483341-108CDB72-2A5C-4BB1-ACA1-B4B747201559

Q36483341-1DD97DCC-EA9A-4D3C-9450-E060E395D099

Q36483341-2D90847A-CB92-4F8C-B89D-71282CE7FECC

Q36483341-394D6433-9393-46C3-A7A7-AB19A592E707

Q36483341-480601DC-BA01-418E-9453-0E953904C5E9

Q36483341-531F2684-6A13-424A-AE16-931ACD7436E2

Q36483341-53D0E6C5-D5FE-4128-9868-E7464FBC0B11

Q36483341-591A8E40-D18E-486A-869B-6F72575554A8

P304

Q36483341-4CF4BBD6-CF3B-48E4-8B6A-884B21FFDFB2

P31

Q36483341-C16EC903-3D2E-4034-9909-CA8E2C5333AE

P356

Q36483341-215F42A4-C03B-4910-ADB3-FD8F7911B73D

P407

Q36483341-8022AEE6-A2E0-4566-95EC-A6F61E3F3228

P433

Q36483341-DD7B2A5D-3B62-4F6D-8E02-F21810471D7E

P478

Q36483341-44FC568F-AA52-4AFC-AB6A-1F306D26ED47

P50

Q36483341-2DA8DA94-55B5-4911-9F27-D6F040491FC9

P577

Q36483341-06F7E454-03ED-4CAC-906F-C39CF66BDE57

P698

Q36483341-88B49300-D654-4C3F-B764-9EDAADCA5C7F

P921

Q36483341-1D0B8282-6A43-464B-A5AF-26128AB94D84

P932

Q36483341-3A2A7F79-796A-426C-9735-D1B2D78C1DDC

P356

P1433

Journal of Virology

P1476

Human papillomavirus type 16 a ...... phase I escalating-dose trial

@en

P2093

Alessandro D Santin

http://www.w3.org/2001/XMLSchema#string

Alessandro Zanolini

http://www.w3.org/2001/XMLSchema#string

Eric R Siegel

http://www.w3.org/2001/XMLSchema#string

Juan J Roman

http://www.w3.org/2001/XMLSchema#string

Martin J Cannon

http://www.w3.org/2001/XMLSchema#string

Michela Palmieri

http://www.w3.org/2001/XMLSchema#string

Sergio Pecorelli

http://www.w3.org/2001/XMLSchema#string

Stefania Bellone

http://www.w3.org/2001/XMLSchema#string

P2860

Dendritic cells and the control of immunity

Cancer statistics, 2006

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer

Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells.

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group.

Issues in the meta-analysis of cluster randomized trials.

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma.

Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help.

Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes

P304

1968-1979

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.02343-07

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

82

http://www.w3.org/2001/XMLSchema#string

P50

Antonella Ravaggi

P577

2007-12-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18057249

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

2258728

http://www.w3.org/2001/XMLSchema#string